Chemotherapy non-drug concept codes
Codelist metadata
-
Coding system
- SNOMED CT
-
Coding system release
- 39.2.0
-
Organisation
- NHSD Primary Care Domain Refsets
-
Codelist ID
- nhsd-primary-care-domain-refsets/chemotherapy-non-drug-concept-codes
-
Version Tag
- 20241205
-
Version ID
- 7000bac8
Versions
About
Description
Taken from the CHEMO_COD refset published by NHSD.
Codelists are developed by a broad community of users for individual study purposes, which may or may not meet the needs of other studies. They should not be thought of as universal definitions of a particular condition.
We don't offer any guarantees about what they do or don't identify. Users should carefully check that any codelist meets their needs, and seek clinical input where appropriate.
| code | term |
|---|---|
| 10075000 | Photochemotherapy with tar and ultraviolet B |
| 103081004 | Immunodeficiency secondary to chemotherapy |
| 1035621000000102 | Resistance to antineoplastic drug |
| 1035631000000100 | Resistance to antineoplastic drugs |
| 1064281000000106 | Cancer chemotherapy management plan |
| 109256003 | Mucositis following chemotherapy |
| 110264005 | Effects of chemotherapy |
| 1141994004 | Rituximab, cyclophosphamide, etoposide, vincristine, prednisone antineoplastic chemotherapy regimen |
| 1148692008 | Radiation therapy following chemotherapy |
| 1167461000000101 | Intra-arterial injection of antineoplastic agent into left ophthalmic artery using fluoroscopic guidance with contrast |
| 1167471000000108 | Intra-arterial injection of antineoplastic agent into right ophthalmic artery using fluoroscopic guidance with contrast |
| 1167481000000105 | Intra-arterial injection of antineoplastic agent into bilateral ophthalmic arteries using fluoroscopic guidance with contrast |
| 1172516002 | High-dose chemotherapy with stem cell transplant |
| 118791000119106 | Aplastic anemia caused by antineoplastic agent |
| 118911000119104 | Long-term current use of lenalidomide |
| 1197521004 | Inflammation of mucous membrane due to and following chemotherapy |
| 1197527000 | Ulcerative inflammation of oral mucous membrane due to and following administration of antineoplastic agent |
| 12149006 | Chemotherapy administration, subcutaneous, with local anesthesia |
| 1217525002 | Injection of antineoplastic agent into neoplasm of brain tissue |
| 125211000119106 | History of antineoplastic chemotherapy |
| 1254741007 | Intensification antineoplastic therapy regimen |
| 1254742000 | Delayed intensification antineoplastic therapy regimen |
| 1255831008 | Chemotherapy for malignant neoplastic disease using targeted agent |
| 1255834000 | Administration of antineoplastic chemotherapy into peritoneal cavity |
| 1255904006 | Administration of palliative antineoplastic agent |
| 1259200004 | Neoadjuvant antineoplastic chemotherapy |
| 1264382006 | Follow-up for combined therapy of radiation therapy and chemotherapy |
| 1264383001 | Follow-up for combined therapy of surgery and chemotherapy |
| 1264385008 | Follow-up for combined therapy of surgery, radiation therapy, and chemotherapy |
| 1279827005 | Neoadjuvant antineoplastic therapy procedure prior to surgery |
| 129663002 | Neurotoxicity caused by vincristine |
| 129665009 | Neurotoxicity caused by L-asparaginase |
| 1362501000000105 | Laparoscopic administration of pressurised aerosol antineoplastic agent into peritoneal cavity |
| 136281000119109 | Anemia caused by antineoplastic agent |
| 138918002 | H/O: chemotherapy |
| 146562008 | External beam - surgery with chemotherapy |
| 146563003 | External beam with chemotherapy |
| 146623009 | Radiomimetic chemotherapy |
| 146624003 | Radiochemotherapy: local infiltration |
| 146625002 | Radiochemotherapy: to stop spread |
| 146626001 | Radiochemotherapy: oral route |
| 146627005 | Radiochemotherapy: IV route |
| 146628000 | Radiochemotherapy: for immunosuppression |
| 146629008 | Radiochemotherapy: local artery |
| 146630003 | Radiochemotherapy: into cavity |
| 146631004 | Radiochemotherapy NOS |
| 147696002 | Prophylactic chemotherapy |
| 147704001 | Prophylactic chemotherapy NOS |
| 14836003 | Radiation recall syndrome |
| 150415003 | Chemotherapy |
| 150466008 | Intravenous chemotherapy |
| 151250002 | Oral chemotherapy (& cytotoxic) |
| 151261005 | Ambulatory chemotherapy |
| 151608008 | Convalescence after chemotherapy |
| 151882008 | Chemotherapy follow-up |
| 161653008 | History of chemotherapy |
| 1680000 | Secondary chemoprophylaxis |
| 169335009 | External beam - surgery with chemotherapy |
| 169336005 | External beam radiation therapy with chemotherapy |
| 169396008 | Radiomimetic chemotherapy |
| 169397004 | Radiochemotherapy: local infiltration |
| 169398009 | Radiochemotherapy: to stop spread |
| 169399001 | Radiochemotherapy via oral route |
| 169400008 | Radiochemotherapy via intravenous route |
| 169401007 | Radiochemotherapy: for immunosuppression |
| 169402000 | Radiochemotherapy: local artery |
| 169403005 | Radiochemotherapy: into cavity |
| 169404004 | Radiochemotherapy NOS |
| 170445004 | Prophylaxis: [chemotherapy] or [drug] |
| 170452002 | Prophylactic chemotherapy NOS |
| 171765004 | Intrathecal injection of chemotherapeutic agent |
| 180180003 | Continuous infusion of chemotherapy |
| 180222003 | Intravenous therapy: [chemo-] or [drug] |
| 180243002 | Intramuscular therapy: [chemo-] or [drug] |
| 182967006 | Oral chemotherapy (& cytotoxic) |
| 182973007 | Chemotherapy |
| 182974001 | Cancer chemotherapy |
| 182983006 | Ambulatory chemotherapy |
| 183373009 | Convalescence after chemotherapy |
| 183651009 | Chemotherapy follow-up |
| 18846006 | Chemotherapy-induced nausea and vomiting |
| 198551000000104 | Chemotherapy started |
| 212511004 | Antineoplastic antibiotic poisoning NOS |
| 213871000000100 | Chemotherapy started |
| 213881000000103 | Chemotherapy started |
| 218326006 | Adverse reaction caused by antineoplastic antibiotics |
| 218327002 | Adverse reaction to actinomycin D |
| 218328007 | Adverse reaction to bleomycin |
| 218329004 | Adverse reaction to doxorubicin hydrochloride |
| 218330009 | Adverse reaction to mitomycin |
| 218331008 | Adverse reaction to plicamycin |
| 218333006 | Adverse reaction to antineoplastic antibiotics NOS |
| 218505007 | Adverse reaction to busulfan |
| 218506008 | Adverse reaction to carmustine |
| 218507004 | Adverse reaction to chlorambucil |
| 218508009 | Adverse reaction to cyclophosphamide |
| 218509001 | Adverse reaction to estramustine phosphate |
| 218510006 | Adverse reaction to lomustine |
| 218511005 | Adverse reaction to melphalan |
| 218512003 | Adverse reaction to mustine hydrochloride |
| 218513008 | Adverse reaction to thiotepa |
| 218515001 | Adverse reaction to cytarabine |
| 218517009 | Adverse reaction to mercaptopurine |
| 218519007 | Adverse reaction to thioguanine |
| 218520001 | Adverse reaction to etoposide |
| 218521002 | Adverse reaction to vinblastine sulfate |
| 218522009 | Adverse reaction to vincristine sulfate |
| 218523004 | Adverse reaction to carboplatin |
| 218524005 | Adverse reaction to cisplatin |
| 218525006 | Adverse reaction to hydroxyurea |
| 218526007 | Adverse reaction to mitozantrone |
| 218527003 | Adverse reaction to procarbazine |
| 218528008 | Adverse reaction to razoxane |
| 222985009 | [X]Antineoplastic antimetabolites causing adverse effects in therapeutic use |
| 222986005 | [X]Antineoplastic natural products causing adverse effects in therapeutic use |
| 222987001 | [X]Other antineoplastic drugs causing adverse effects in therapeutic use |
| 225300003 | Photochemotherapy |
| 22638002 | Photochemotherapy with tar and petrolatum |
| 22733003 | Chemotherapy for non-malignant neoplasm |
| 230857009 | Injection of chemotherapeutic substance into subcutaneous reservoir |
| 232681000000103 | Chemotherapy delivery |
| 235331000000103 | Delivery of oral chemotherapy for neoplasm |
| 235391000000102 | Delivery of chemotherapy for neoplasm |
| 236084000 | Chemotherapy sickness |
| 238519000 | Photochemotherapy reaction |
| 238811000000106 | Delivery of oral chemotherapy for neoplasm NOS |
| 238831000000103 | Delivery of exclusively oral chemotherapy for neoplasm |
| 238841000000107 | Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at first attendance |
| 238851000000105 | Delivery of complex parenteral chemotherapy for neoplasm at first attendance |
| 238861000000108 | Delivery of simple parenteral chemotherapy for neoplasm at first attendance |
| 238871000000101 | Delivery of chemotherapy for neoplasm NOS |
| 239071000000100 | Delivery of subsequent element of cycle of chemotherapy for neoplasm |
| 239081000000103 | Other specified delivery of chemotherapy for neoplasm |
| 239091000000101 | Other specified delivery of oral chemotherapy for neoplasm |
| 240251000000107 | Problems following chemotherapy |
| 243571000000108 | Symptoms due to chemotherapy |
| 25081000000105 | Chemotherapy changed - acute chemotherapy toxicity |
| 25091000000107 | Chemotherapy changed - patient choice |
| 25521000000102 | Chemotherapy changed - progressive disease during chemotherapy |
| 25531000000100 | Chemotherapy changed - technical or organisational problems |
| 262502001 | Post-chemotherapy |
| 265760000 | Intravenous chemotherapy |
| 265761001 | Intramuscular chemotherapy |
| 265762008 | Subcutaneous chemotherapy |
| 266719004 | Oral chemotherapy |
| 267901000000108 | Delivery of chemotherapy for neoplasm |
| 267911000000105 | Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at first attendance |
| 267921000000104 | Delivery of complex parenteral chemotherapy for neoplasm at first attendance |
| 267931000000102 | Delivery of simple parenteral chemotherapy for neoplasm at first attendance |
| 267941000000106 | Delivery of subsequent element of cycle of chemotherapy for neoplasm |
| 267951000000109 | Other specified delivery of chemotherapy for neoplasm |
| 267961000000107 | Delivery of chemotherapy for neoplasm NOS |
| 267971000000100 | Delivery of oral chemotherapy for neoplasm |
| 267981000000103 | Delivery of exclusively oral chemotherapy for neoplasm |
| 267991000000101 | Other specified delivery of oral chemotherapy for neoplasm |
| 268001000000105 | Delivery of oral chemotherapy for neoplasm NOS |
| 268500004 | Administration of prophylactic chemotherapy |
| 282571000000106 | Combined photochemotherapy and ultraviolet A light therapy to skin |
| 282581000000108 | Combined photochemotherapy and ultraviolet B light therapy to skin |
| 288108006 | Cytotoxic drug therapy NOS |
| 290631006 | Triazene antineoplastic poisoning |
| 290721000000104 | Combined photochemotherapy and ultraviolet A light therapy to skin |
| 290731000000102 | Combined photochemotherapy and ultraviolet B light therapy to skin |
| 292190002 | Aldesleukin adverse reaction |
| 292196008 | Antineoplastic adverse reaction |
| 292197004 | Alkylating drug adverse reaction |
| 292198009 | Mitobronitol adverse reaction |
| 292199001 | Busulfan adverse reaction |
| 292200003 | Treosulfan adverse reaction |
| 292201004 | Thiotepa adverse reaction |
| 292202006 | Nitrogen mustard derivative adverse reaction |
| 292203001 | Chlorambucil adverse reaction |
| 292204007 | Cyclophosphamide adverse reaction |
| 292205008 | Ethoglucid adverse reaction |
| 292206009 | Ifosfamide adverse reaction |
| 292207000 | Melphalan adverse reaction |
| 292208005 | Estramustine adverse reaction |
| 292209002 | Mustine adverse reaction |
| 292210007 | Nitrosurea adverse reaction |
| 292212004 | Carmustine adverse reaction |
| 292213009 | Lomustine adverse reaction |
| 292214003 | Triazene antineoplastic adverse reaction |
| 292215002 | Dacarbazine adverse reaction |
| 292216001 | Cytotoxic antibiotic adverse reaction |
| 292217005 | Dactinomycin adverse reaction |
| 292218000 | Bleomycin adverse reaction |
| 292220002 | Mitomycin adverse reaction |
| 292221003 | Plicamycin adverse reaction |
| 292222005 | Aclarubicin adverse reaction |
| 292223000 | Mitozantrone adverse reaction |
| 292224006 | Doxorubicin adverse reaction |
| 292225007 | Epirubicin adverse reaction |
| 292226008 | Idarubicin adverse reaction |
| 292230006 | Mercaptopurine adverse reaction |
| 292231005 | Thioguanine adverse reaction |
| 292232003 | Pentostatin adverse reaction |
| 292233008 | Cytarabine adverse reaction |
| 292235001 | Etoposide adverse reaction |
| 292236000 | Amsacrine adverse reaction |
| 292237009 | Carboplatin adverse reaction |
| 292238004 | Cisplatin adverse reaction |
| 292239007 | Hydroxyurea adverse reaction |
| 292240009 | Procarbazine adverse reaction |
| 292241008 | Razoxane adverse reaction |
| 292242001 | Crisantaspase adverse reaction |
| 292243006 | Paclitaxel adverse reaction |
| 292244000 | Fludarabine adverse reaction |
| 292245004 | Aminoglutethimide adverse reaction |
| 292250005 | Vinca alkaloid adverse reaction |
| 292251009 | Vinblastine adverse reaction |
| 292252002 | Vincristine adverse reaction |
| 292253007 | Vindesine adverse reaction |
| 292838008 | Interferon-A-2b adverse reaction |
| 29391003 | Chemotherapy administration into peritoneal cavity requiring paracentesis |
| 295653006 | Triazene antineoplastic overdose |
| 29722002 | Photochemotherapy with petrolatum and ultraviolet B |
| 309698005 | Continuous infusion of chemotherapy |
| 315601005 | Ambulatory chemotherapy |
| 315725008 | [V]Other prophylactic chemotherapy |
| 316331002 | [V]Maintenance chemotherapy |
| 316338008 | [V]Chemotherapy session for neoplasm |
| 316440004 | [V]Convalescence after chemotherapy |
| 316449003 | [V]Chemotherapy follow-up |
| 316455008 | [V]Follow-up examination after chemotherapy for malignant neoplasm |
| 316474000 | [V]Follow-up examination after chemotherapy for other conditions |
| 31652009 | Intracavitary chemotherapy for malignant neoplasm |
| 316718009 | [X]Follow-up examination after chemotherapy for other conditions |
| 316742008 | [X]Need for other prophylactic chemotherapy |
| 316783006 | [X]Other chemotherapy |
| 328301000119102 | Pancytopenia due to antineoplastic chemotherapy |
| 33762001 | Primary chemoprophylaxis |
| 348791000000100 | Goeckerman regime |
| 350691000119103 | Agranulocytosis due to and following administration of antineoplastic agent |
| 363688001 | Administration of antineoplastic agent |
| 367336001 | Chemotherapy |
| 37037008 | Prescription of a prophylactic chemotherapeutic agent |
| 371135000 | Delay of chemotherapy |
| 373832009 | Reason for change in planned chemotherapy treatment |
| 373833004 | Chemotherapy changed - progressive disease during chemotherapy |
| 373834005 | Chemotherapy changed - acute chemotherapy toxicity |
| 373835006 | Chemotherapy changed due to technical or organizational problems |
| 373836007 | Chemotherapy changed - patient choice |
| 38216008 | Infusion chemotherapy for malignant neoplasm |
| 385786002 | Chemotherapy care |
| 385788001 | Chemotherapy care management |
| 393096004 | Pre-operative chemotherapy |
| 393097008 | Post-operartive chemotherapy |
| 393098003 | Combined pre-operative chemotherapy and radiotherapy |
| 393099006 | Combined post-operative chemotherapy and radiotherapy |
| 394047001 | Pre-operative chemotherapy |
| 394048006 | Post-operartive chemotherapy |
| 394049003 | Combined pre-operative chemotherapy and radiotherapy |
| 394050003 | Combined post-operative chemotherapy and radiotherapy |
| 394101000000106 | [X]Antineoplastic antimetabolites causing adverse effects in therapeutic use |
| 394894008 | Pre-operative chemotherapy |
| 394895009 | Postoperative chemotherapy |
| 394900008 | Administration of cancer treatment |
| 394934009 | Combined preoperative chemotherapy and radiotherapy |
| 394935005 | Combined postoperative chemotherapy and radiotherapy |
| 396780003 | Chemotherapy AND/OR radiation therapy prior to lymphadenectomy |
| 399042005 | Chemotherapy cycle |
| 399213007 | Toxicity due to chemotherapy |
| 400001000004103 | Neoadjuvant antineoplastic therapy |
| 402752000 | Dermatosis due to cytotoxic therapy |
| 403637008 | Cutaneous inflammation due to cytotoxic therapy |
| 403638003 | Acral erythema due to cytotoxic therapy |
| 403639006 | Syringosquamous metaplasia due to cytotoxic therapy |
| 403640008 | Neutrophilic eccrine hidradenitis due to cytotoxic therapy |
| 403641007 | Pseudoscleroderma due to cytotoxic therapy |
| 403642000 | Cutaneous ulceration due to cytotoxic therapy |
| 403644004 | Radiation recall reaction due to cytotoxic therapy |
| 403645003 | Ultraviolet recall reaction due to cytotoxic therapy |
| 403710000 | Adverse effect from psoralen and long-wave ultraviolet radiation photochemotherapy |
| 406221000000107 | [X]Antineoplastic natural products causing adverse effects in therapeutic use |
| 409760003 | Status of histological necrosis after induction chemotherapy |
| 409761004 | Histological necrosis absent after induction chemotherapy |
| 409762006 | Histological necrosis present after induction chemotherapy |
| 409763001 | Histological necrosis after induction chemotherapy cannot be determined |
| 409764007 | Percentage of histological necrosis after induction chemotherapy |
| 4114003 | Parenteral chemotherapy for malignant neoplasm |
| 413771000000109 | [V]Follow-up examination after chemotherapy for malignant neoplasm |
| 420965003 | Administration of prophylactic antineoplastic agent |
| 423661009 | Complication of chemotherapy |
| 425229001 | Chemotherapy-induced neutropenia |
| 427069009 | Azoospermia due to chemotherapy AND/OR radiation |
| 428083009 | Combined photochemotherapy and ultraviolet B light therapy to skin |
| 428221000000101 | [V]Convalescence after chemotherapy |
| 428501000000108 | [V]Chemotherapy session for neoplasm |
| 428908000 | Combined photochemotherapy and ultraviolet A light therapy to skin |
| 429564000 | Anemia caused by chemotherapy |
| 430328004 | Inflammation of esophagus due to chemotherapy |
| 441858005 | Adverse reaction caused by trastuzumab administered by infusion |
| 442108004 | Adverse reaction caused by rituximab administered by infusion |
| 442760001 | Thrombophilia due to antineoplastic agent therapy |
| 446468007 | Cellular atypia caused by antineoplastic agent |
| 447053005 | Oxaliplatin desensitization therapy |
| 447171000000108 | [X]Other antineoplastic drugs causing adverse effects in therapeutic use |
| 450827009 | Induction chemotherapy |
| 451691000000109 | [V]Other prophylactic chemotherapy |
| 452971000000105 | [V]Chemotherapy follow-up |
| 453671000000106 | [V]Follow-up examination after chemotherapy for other conditions |
| 45747003 | Poisoning caused by antineoplastic antibiotic |
| 46467001 | Photochemotherapy with psoralens and ultraviolet A |
| 465401000000105 | [X]Need for other prophylactic chemotherapy |
| 468111000000107 | [X]Other chemotherapy |
| 469981000000107 | [V]Maintenance chemotherapy |
| 479871000000108 | [X]Follow-up examination after chemotherapy for other conditions |
| 50050121000188109 | Arsenic and/or arsenic compound therapy |
| 51534007 | Oral chemotherapy for malignant neoplasm |
| 52166007 | Pleurodesis with cancer chemotherapy substance |
| 53523003 | Poisoning caused by cactinomycin |
| 545141000000103 | Prophylactic chemotherapy NOS |
| 562601000000107 | Radiochemotherapy NOS |
| 671071000000100 | Adverse reaction to antineoplastic antibiotics NOS |
| 675231000000108 | Cytotoxic drug therapy NOS |
| 68619000 | Chemotherapy for non-neoplastic disease |
| 6872008 | Perfusion chemotherapy for malignant neoplasm |
| 69960004 | Antineoplastic chemotherapy regimen |
| 700496000 | Postoperative administration of antineoplastic agent into peritoneal cavity |
| 700504007 | Post-chemotherapy monitoring |
| 703423002 | Combined chemotherapy and radiation therapy |
| 70446004 | Chemotherapy administration into pleural cavity requiring thoracentesis |
| 707088000 | Peripheral neuropathy due to chemotherapy |
| 710111000000100 | Cancer chemotherapy management plan |
| 710121000000106 | Cancer chemotherapy management plan |
| 716872004 | Antineoplastic chemotherapy regimen |
| 720379009 | Hepatic arterial infusion chemotherapy |
| 720469008 | Azoospermia caused by chemotherapy |
| 720580006 | Resistance to antineoplastic drug |
| 722472009 | Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
| 722480002 | Chemotherapy started |
| 722482005 | Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
| 722491009 | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
| 725054001 | Chemotherapy-induced change |
| 725056004 | Reactive cellular changes associated with chemotherapy |
| 726600009 | Lenalidomide therapy |
| 736401008 | Chemotherapy care plan |
| 762315004 | Therapy related acute myeloid leukemia due to and following administration of antineoplastic agent |
| 762595001 | Chronic painful polyneuropathy following chemotherapy |
| 766045006 | Acute myeloid leukemia and myelodysplastic syndrome related to alkylating agent |
| 767657005 | Anemia due to and following chemotherapy |
| 767658000 | Neutropenia due to and following chemotherapy |
| 767659008 | Peripheral neuropathy due to and following antineoplastic therapy |
| 773537001 | Differentiation syndrome due to and following chemotherapy co-occurrent with acute promyelocytic leukemia |
| 77738002 | Local chemotherapy for malignant neoplasm |
| 784317004 | Fatigue due to chemotherapy |
| 803941000000109 | Induction chemotherapy |
| 816151001 | Administration of consolidation antineoplastic agent |
| 819971000000103 | Hyperthermic intraoperative peritoneal chemotherapy |
| 82350007 | Photochemotherapy |
| 829591000000101 | Neoadjuvant chemotherapy |
| 830155008 | Administration of hyperthermic antineoplastic agent into peritoneal cavity |
| 830156009 | Administration of hyperthermic antineoplastic agent into thoracic cavity |
| 833041000000100 | H/O: chemotherapy |
| 834441000000106 | Neoadjuvant chemotherapy |
| 840431000000109 | Acute renal failure induced by cisplatin |
| 841901000000104 | Provision of chemotherapy alert card |
| 843671000000104 | Electrochemotherapy |
| 847541000000102 | Intra-arterial infusion of antineoplastic agent using fluoroscopic guidance with contrast |
| 847581000000105 | Intra-arterial injection of antineoplastic agent into ophthalmic artery using fluoroscopic guidance with contrast |
| 847641000000103 | Infusion of antineoplastic agent into cerebral artery using fluoroscopic guidance with contrast |
| 851351000000101 | Chemotherapy care plan |
| 857171000000101 | Electrochemotherapy |
| 86036005 | Intravenous chemotherapy administration by push technique |
| 862921000000106 | Intravesical electrochemotherapy |
| 870249004 | Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen |
| 870250004 | Fluorouracil, leucovorin, irinotecan and oxaliplatin antineoplastic chemotherapy regimen |
| 871775006 | Adverse reaction to triazene |
| 871783000 | Adverse reaction to arsenic and/or arsenic compound |
| 87776000 | Intra-arterial infusion of antineoplastic agent |
| 882661000000108 | Postoperative intraperitoneal chemotherapy |
| 883511000000103 | Post-chemotherapy monitoring |
| 890093004 | Administration of multiple antineoplastic agents |
| 897713009 | Antineoplastic chemoimmunotherapy |
| 97201000119101 | Fatigue due to chemotherapy or radiation therapy |
| 98901000119106 | Ulcerative mucositis due to non-antineoplastic therapy |
Codes not in the full codelist are in faint grey.